Parmax Pharma

{
  "main_header": {
    "sid": 1002724,
    "name": "Parmax Pharma",
    "stock_name": "Parmax Pharma",
    "full_name": "Parmax Pharma Ltd",
    "name_url": "stocks-analysis/parmax-pharma",
    "exchange": 0,
    "exchangecode": "",
    "primexch": 0,
    "country_id": 34,
    "currency": "INR",
    "cmp": "27.83",
    "chg": 0.28,
    "chgp": "1.02%",
    "dir": 1,
    "prev_price": "27.55",
    "mcapval": "10.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": 540359,
    "symbol": "",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "India SENSEX",
    "isin": "INE240T01014",
    "curr_date": "Mar 19",
    "curr_time": "",
    "bse_nse_vol": "144 ",
    "exc_status": "Active",
    "traded_date": "Mar 19, 2026",
    "traded_date_str": "2026 03 19",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/parmax-pharma-1002724-0&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Parmax Pharma Ltd Falls to 52-Week Low of Rs 24.5 Amidst Continued Weakness",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-falls-to-52-week-low-of-rs-245-amidst-continued-weakness-3898506",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ParmaxPharmaLtd_priceRelatedfactors_3898506.png",
        "date": "2026-03-18 10:04:09",
        "description": "Parmax Pharma Ltd, a micro-cap entity in the Pharmaceuticals & Biotechnology sector, has declined sharply to a new 52-week low of Rs.24.5, marking a significant drop of 11.71% in today’s trading session. This fresh low underscores the stock’s ongoing underperformance relative to its sector and broader market indices."
      },
      {
        "title": "Parmax Pharma Ltd Falls to 52-Week Low of Rs 25 Amidst Weak Financials",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/parmax-pharma-ltd-falls-to-52-week-low-of-rs-25-amidst-weak-financials-3887189",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/3/ParmaxPharmaLtd_priceRelatedfactors_3887189.png",
        "date": "2026-03-12 14:57:13",
        "description": "Parmax Pharma Ltd’s shares declined sharply to a new 52-week low of Rs.25 on 12 Mar 2026, marking a significant downturn amid ongoing financial headwinds and sector underperformance. The stock’s recent volatility and sustained downward trend reflect persistent challenges in the company’s financial metrics and market positioning."
      },
      {
        "title": "Parmax Pharma Q3 FY26: Mounting Losses Deepen as Revenue Plummets 72% YoY",
        "link": "https://www.marketsmojo.com/news/result-analysis/parmax-pharma-q3-fy26-mounting-losses-deepen-as-revenue-plummets-72-yoy-3842936",
        "imagepath": "https://i.marketsmojo.com/newsimg/2026/2/ParmaxPharma_quaterlyResult_3842936.png",
        "date": "2026-02-16 22:05:05",
        "description": "Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), has reported deeply concerning financial results for Q3 FY26, with net losses widening to ₹0.73 crores whilst revenues collapsed 72.74% year-on-year to ₹2.53 crores. The company, trading at ₹32.00 with a market capitalisation of just ₹12.00 crores, has now recorded consecutive quarterly losses throughout FY26, raising serious questions about operational viability and management execution."
      },
      {
        "title": "When is the next results date for Parmax Pharma Ltd?",
        "link": "https://www.marketsmojo.com/news/result-analysis/when-is-the-next-results-date-for-parmax-pharma-ltd-3833797",
        "imagepath": "",
        "date": "2026-02-11 23:17:17",
        "description": "The next results date for Parmax Pharma Ltd is scheduled for 14 February 2026...."
      },
      {
        "title": "Parmax Pharma Ltd is Rated Strong Sell",
        "link": "https://www.marketsmojo.com/news/stock-recommendation/parmax-pharma-ltd-is-rated-strong-sell-3771013",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/12/ParmaxPharmaLtd_mojoScore_3771013.png",
        "date": "2025-12-26 15:13:06",
        "description": "Parmax Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 June 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 December 2025, providing investors with the latest comprehensive analysis."
      },
      {
        "title": "Why is Parmax Pharma falling/rising?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/why-is-parmax-pharma-fallingrising-3764375",
        "imagepath": "",
        "date": "2025-12-20 02:32:50",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Current Market Performance and Price Movement</strong></p>\n<p>On 19 December, Parmax Pharma’s shares experienced a significant intraday decline, touching a low of ₹31.00, down ₹2.63 from the previous close. This drop represents an underperformance of 8.57% against its sector, with the weighted average price indicating that most trading volume occurred near the day’s low. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak investor sentiment.</p>\n<p>Investor participation has also waned, with delivery volumes on 18 December falling by 27.84% compared to the five-day average, suggesting reduced confidence among shareholders. Despite adequate liquidity for trading, the stock’s downward moment..."
      }
    ],
    "total": 115,
    "sid": "1002724",
    "stock_news_url": "https://www.marketsmojo.com/news/parmax-pharma-1002724"
  },
  "announcements": [
    {
      "caption": "Board Meeting Outcome for Outcome Of Board Meeting",
      "datetime": "14-Feb-2026",
      "details": "Outcome of Board meeting for Financial Results",
      "source": "BSE"
    },
    {
      "caption": "Unaudited Financial Results For Quarter And Nine Months Ended 31.12.2025",
      "datetime": "14-Feb-2026",
      "details": "Unaudited Financial results for quarter and Nine months ended 31.12.2025",
      "source": "BSE"
    },
    {
      "caption": "Board Meeting Intimation for Consider And Approve Unaudited Financial Results For Quarter And Nine Months Ended On December 31 2025",
      "datetime": "09-Feb-2026",
      "details": "Parmax Pharma Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/02/2026 inter alia to consider and approve Unaudited Financial results for quarter and nine months ended on December 31 2025",
      "source": "BSE"
    }
  ],
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Parmax Pharma Ltd Falls to 52-Week Low of Rs 24.5 Amidst Continued Weakness

2026-03-18 10:04:09

Parmax Pharma Ltd, a micro-cap entity in the Pharmaceuticals & Biotechnology sector, has declined sharply to a new 52-week low of Rs.24.5, marking a significant drop of 11.71% in today’s trading session. This fresh low underscores the stock’s ongoing underperformance relative to its sector and broader market indices.

Read full news article

Parmax Pharma Ltd Falls to 52-Week Low of Rs 25 Amidst Weak Financials

2026-03-12 14:57:13

Parmax Pharma Ltd’s shares declined sharply to a new 52-week low of Rs.25 on 12 Mar 2026, marking a significant downturn amid ongoing financial headwinds and sector underperformance. The stock’s recent volatility and sustained downward trend reflect persistent challenges in the company’s financial metrics and market positioning.

Read full news article

Parmax Pharma Q3 FY26: Mounting Losses Deepen as Revenue Plummets 72% YoY

2026-02-16 22:05:05

Parmax Pharma Ltd., a micro-cap pharmaceutical company specialising in Active Pharmaceutical Ingredients (API) and Contract Manufacturing Operations (CMO), has reported deeply concerning financial results for Q3 FY26, with net losses widening to ₹0.73 crores whilst revenues collapsed 72.74% year-on-year to ₹2.53 crores. The company, trading at ₹32.00 with a market capitalisation of just ₹12.00 crores, has now recorded consecutive quarterly losses throughout FY26, raising serious questions about operational viability and management execution.

Read full news article

When is the next results date for Parmax Pharma Ltd?

2026-02-11 23:17:17

The next results date for Parmax Pharma Ltd is scheduled for 14 February 2026....

Read full news article

Parmax Pharma Ltd is Rated Strong Sell

2025-12-26 15:13:06

Parmax Pharma Ltd is rated Strong Sell by MarketsMOJO. This rating was last updated on 16 June 2025, reflecting a significant reassessment of the stock’s outlook. However, all fundamentals, returns, and financial metrics discussed below are based on the company’s current position as of 26 December 2025, providing investors with the latest comprehensive analysis.

Read full news article

Why is Parmax Pharma falling/rising?

2025-12-20 02:32:50

Current Market Performance and Price Movement

On 19 December, Parmax Pharma’s shares experienced a significant intraday decline, touching a low of ₹31.00, down ₹2.63 from the previous close. This drop represents an underperformance of 8.57% against its sector, with the weighted average price indicating that most trading volume occurred near the day’s low. The stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, signalling a bearish trend and weak investor sentiment.

Investor participation has also waned, with delivery volumes on 18 December falling by 27.84% compared to the five-day average, suggesting reduced confidence among shareholders. Despite adequate liquidity for trading, the stock’s downward moment...

Read full news article

View All News